# Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

> **NCT00313053** · PHASE1 · TERMINATED · sponsor: **Clare Twist** · enrollment: 4 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Acute
- Leukemia
- Acute Lymphoid Leukemia (ALL)

## Interventions

- **DRUG:** Human mAb 216
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00313053
- **Lead sponsor:** Clare Twist
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2008-04
- **Final completion:** 2008-07
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2016-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313053, "Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00313053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*